James Investment Research’s Vanda Pharmaceuticals VNDA Stock Holding History

James Investment Research’s Portfolio VNDA Stock Details VNDA Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2023 Q1	–	Sell	-43,517	Closed	-$322K	–	644
2022 Q4	$322K	Sell	43,517 -565	-1%	-$5.5K	0.05%	215
2022 Q3	$436K	Hold	44,082	–	–	0.06%	186
2022 Q2	$480K	Hold	44,082	–	–	0.06%	183
2022 Q1	$499K	Hold	44,082	–	–	0.05%	201
2021 Q4	$692K	Hold	44,082	–	–	0.06%	183
2021 Q3	$756K	Hold	44,082	–	–	0.07%	171
2021 Q2	$948K	Hold	44,082	–	–	0.08%	158
2021 Q1	$662K	Buy	44,082 +24,372	+124%	+$395K	0.06%	180
2020 Q4	$259K	Buy	19,710 +25	+0.1%	+$301	0.02%	246
2020 Q3	$190K	Hold	19,685	–	–	0.02%	257
2020 Q2	$225K	Buy	19,685 +1,505	+8%	+$17K	0.02%	240
2020 Q1	$188K	Buy	+18,180	New	+$225K	0.02%	234
2019 Q1	–	Sell	-41,400	Closed	-$1.08M	–	913
2018 Q4	$1.08M	Buy	+41,400	New	+$973K	0.07%	290

Other funds holding VNDA

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Renaissance Technologies New York $72.6B AUM 54.88% 1-Year Est. Return

Dimensional Fund Advisors Austin, Texas $552B AUM 44.19% 1-Year Est. Return

Millennium Management New York $276B AUM 44.8% 1-Year Est. Return

Goldman Sachs New York $1.15T AUM 47.82% 1-Year Est. Return

Bank of America Charlotte, North Carolina $1.55T AUM 33.47% 1-Year Est. Return

Assenagon Asset Management Senningerberg, Luxembourg $80.2B AUM 50.56% 1-Year Est. Return

D.E. Shaw & Co New York $210B AUM 57.28% 1-Year Est. Return

James Investment Research's VNDA Position: Q1 2023 in Review

James Investment Research sold out of Vanda Pharmaceuticals (VNDA) in Q1 2023, closing a stake of 43,517 shares — an estimated $322K sold.

James Investment Research first reported a position in VNDA in Q4 2018 and held it in 13 quarters. The position peaked at $1.08M in Q4 2018. 177 funds tracked by Wall St. Rank hold VNDA as of Q1 2023.

James Investment Research reported no remaining Vanda Pharmaceuticals position as of Q1 2023 after selling out during the quarter.
James Investment Research sold 43,517 Vanda Pharmaceuticals shares in Q1 2023, an estimated $322K.
James Investment Research first reported a position in Vanda Pharmaceuticals in Q4 2018 and held it in 13 quarters.
James Investment Research's Vanda Pharmaceuticals position peaked at $1.08M in Q4 2018.
177 funds tracked by Wall St. Rank held Vanda Pharmaceuticals as of Q1 2023.

Based on James Investment Research's 13F filing for Q1 2023, filed 26 Apr 2023.